By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Roche: fat fighter drugs buy must precede trial wins
News

Roche: fat fighter drugs buy must precede trial wins

News Room
Last updated: 2023/12/04 at 11:56 PM
By News Room
Share
3 Min Read
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

In a race, any place but first can feel like coming last. That is not the case for pharmaceutical companies. Novo Nordisk and Eli Lilly are already striding ahead with anti-obesity treatments. But prizes are still on offer for also-rans, especially if they can compete on price. Barclays estimates the market could be worth $100bn within a decade,

Switzerland’s Roche has just boosted its chances of being a contender. It is acquiring US-based obesity drugs developer Carmot Therapeutics for up to $3.1bn. It is the second bolt-on acquisition by Roche’s new chief executive Thomas Schinecker in less than two months.

Schinecker needs to soothe investor jitters over Roche’s pipeline. The group had several big disappointments in 2022. These included trial failures by its Alzheimer’s drug, gantenerumab.

The Carmot deal will give Roche access to three clinical stage assets based on GLP-1 treatments for obesity. These drugs are similar to Eli Lilly’s much-discussed Mounjaro. Others are joining the obesity drug race: AstraZeneca in November struck a $2bn licensing agreement with China’s Eccogene.

Two of the Carmot treatments are injectable, including snappily named lead asset CT-388. The other is in pill form — the Holy Grail of anti-obesity medicines. But only data for one out of three trial stages is available for CT-388. That would explain the modest 2.5 per cent rise in Roche’s share price on Monday. Year-to-date, the stock is still down more than 15 per cent.

Roche trades on a forward price/earnings ratio of 12.4 times, behind its five-year average of just over 15 times.

Schinecker has been trying hard to persuade investors Roche has one of the youngest drug portfolios in the business. It has 98 pipeline assets in various phases, well ahead of a sector average of 70. Its problem is that phase 3 trial success rates have fallen below sector averages.

Schinecker will have to better that hit rate if he is to persuade investors that Roche’s losing streak is behind it.

Read the full article here

News Room December 4, 2023 December 4, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Ukrainian commander describes ‘culture of fear’ in armed forces

Stay informed with free updatesSimply sign up to the War in Ukraine…

Strengthening EU defence won’t undermine the transatlantic alliance

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

General Atlantic follows Apollo in halting early recruitment of bankers

Stay informed with free updatesSimply sign up to the Private equity myFT…

Only a crisis will wean the west off debt

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

UN atomic watchdog rebukes Iran over nuclear breaches

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

News

Ukrainian commander describes ‘culture of fear’ in armed forces

By News Room
News

Strengthening EU defence won’t undermine the transatlantic alliance

By News Room
News

General Atlantic follows Apollo in halting early recruitment of bankers

By News Room
News

Only a crisis will wean the west off debt

By News Room
News

UN atomic watchdog rebukes Iran over nuclear breaches

By News Room
News

Dollar sinks to three-year low on Trump tariff threat

By News Room
News

Air India flight to London carrying 242 people crashes in Ahmedabad

By News Room
News

China demands sensitive information for rare earth exports, companies warn

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?